Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173377 | 0.88 | LIPE (0.34) | CYP11B2CYP2C9CYP2C19 | |
| SCHEMBL6173900 | 0.86 | IGF1R (0.42) | IGF1R | |
| SCHEMBL6174952 | 0.85 | IGF1R (0.38) | IGF1RCYP2C9CYP2C19 | |
| SCHEMBL6174729 | 0.82 | IGF1R (0.37) | IGF1R | |
| SCHEMBL6172545 | 0.81 | CYP11B2 (0.33) | IGF1RCYP11B2CYP2C9CYP2C19 | |
| SCHEMBL6172542 | 0.81 | IGF1R (0.38) | IGF1RCYP11B2 | |
| SCHEMBL6175279 | 0.80 | FKBP1A (0.37) | IGF1RCYP2C9CYP2C19 | |
| SCHEMBL6172761 | 0.79 | IGF1R (0.42) | IGF1R | |
| SCHEMBL6172115 | 0.79 | IGF1R (0.37) | IGF1RCYP2C9CYP2C19 | |
| SCHEMBL6174921 | 0.78 | IGF1R (0.43) | IGF1RCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |